Vertaling van "types of hormonal contraception—oral versus " (Nederlands → Frans) :

(Guida 2005) Guida M, Di Spiezio Sardo A, Bramante S et al. Effects of two types of hormonal contraception—oral versus intravaginal—on the
(Guida 2005) Guida M, Di Spiezio Sardo A, Bramante S et al. Effects of two types of hormonal contraception—oral versus

Hormonal versus non-hormonal contraceptives in women with diabetes
Hormonal versus non-hormonal contraceptives in

(Gallo 2008/2011) Gallo MF, Nanda K, Grimes DA et al. 20 μg versus > 20 μg estrogen combined oral contraceptives for contraception.
(Gallo 2008) Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight.

Skin patch and vaginal ring versus combined oral contraceptives for contraception.
Skin patch and vaginal ring versus combined oral contraceptives for

(Van Vliet 2006a) Van Vliet HAAM, Grimes DA, Helmerhorst FM et al. Biphasic versus monophasic oral contraceptives for contraception.
(Van Vliet 2006a) Van Vliet HAAM, Grimes DA, Helmerhorst FM et al. Biphasic versus monophasic oral contraceptives for

(Van Vliet 2006c) Van Vliet HAAM, Grimes DA ,Helmerhorst FM et al. Biphasic versus triphasic oral contraceptives for contraception. Cochrane
(Van Vliet 2006c) Van Vliet HAAM, Grimes DA ,Helmerhorst FM et al. Biphasic versus triphasic oral contraceptives for

(Van Vliet 2006b) Van Vliet HAAM, Grimes DA, Lopez LM et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane
(Van Vliet 2006b) Van Vliet HAAM, Grimes DA, Lopez LM et al. Triphasic versus monophasic oral contraceptives for

Galvus/Eucreas (USD 101 million, +114% cc), oral treatments for type 2 diabetes, continued to deliver strong growth, driven mainly by combination treatment Eucreas/Galvusmet which delivered 72% of total sales and grew at +123% (cc) during the third quarter versus the prior year.
Galvus/Eucreas (USD 101 millions, +114% tcc), des traitements par voie orale du diabète de type 2, a continué de croître fortement, grâce principalement au traitement combiné Eucreas/Galvusmet qui a représenté 72% du chiffre d’affaires total et a grimpé de +123% tcc en un an.